Precipio, Inc. PRPO PHARMA

Q: What is the current share price of Precipio, Inc. (PRPO)?

As of 2026-09-19 21:16 PDT, Precipio, Inc. (PRPO) trades at $27.25 on NasdaqCM. Its 52-week range is $14.19 to $32.37.

Q: What is the market capitalisation of PRPO?

Precipio, Inc. (PRPO) has a market capitalisation of $48.78M on NasdaqCM.

Q: What is the P/E ratio of PRPO?

PRPO trades at a trailing price-to-earnings (P/E) ratio of -43.95. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 3.21.

Q: What is the return on equity (ROE) of PRPO?

PRPO has a return on equity (ROE) of -8.98%. Its return on capital employed (ROCE) is -6.84%.

Q: Is PRPO a good stock to buy?

This page provides a data-driven analysis of Precipio, Inc. (PRPO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Diagnostics & Research · United States

https://www.precipiodx.com

Company Profile ↓

$27.25

+90.69% 1Y

Mkt Cap$48.78M

P/E-43.95

P/B3.21

52W High$32.37

52W Low$14.19

Book Value$8.25

EPS (TTM)$-0.62

Company Overview

Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.24.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Dec 2025 Revenue of $24.05M (+29.8% YoY); net profit $-363.00K.
Trailing 12 Months Year-on-year growth — revenue +24.2%.
5-Year Trend Long-term compounding — revenue CAGR 0.6%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	0.59%
1 Year:	24.20%

Stock Price Performance

1 Year:	+90.69%
6 Months:	+6.24%
3 Months:	+18.48%
1 Month:	+13.68%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish

52-Week Range 72% of range

$14.19 $32.37

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMAAbove
RSI (14)53.30 · Neutral

Price Performance

1M+13.68%

3M+18.48%

6M+6.24%

1Y+90.69%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Generates positive free cash flow.

CONS

In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-43.95

Industry PE

24.83

Forward P/E

69.87

PEG Ratio

Book Value

$8.25

Price to Book

3.21

P/S

1.74

EV/EBITDA

-371.17

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

0.59%

Profit 5Y

Revenue (YoY)

24.20%

Earnings (YoY)

Profitability & Returns

ROCE

-6.84%

ROE

-8.98%

ROA

-4.81%

Profit Margin

-4.47%

Op Margin

-8.53%

Gross Margin

44.11%

EPS (Latest Qtr)

$-0.81

EPS (TTM)

$-0.62

Balance Sheet & Liquidity

Debt/Equity

0.24

Quick Ratio

1.45

Current Ratio

1.77

Debt

$3.59M

Total Assets

$20.80M

Current Assets

$5.93M

Working Capital

$2.29M

Ownership

Promoter Holding

12.63%

Chg in Prom Hold

-0.02%

FII / Inst Holding

17.71%

Chg in FII Hold

-0.90%

Financial Snapshot

Enterprise Value

$48.78M

Total Revenue (TTM)

$27.20M

EBITDA

$-129.00K

Free Cash Flow

$1.35M

Operating Cash Flow

$1.10M

Shares Outstanding

1.79M

Gross Margin

44.11%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	PRPO Precipio, Inc. PHARMA	27.25	-43.95	$48.78M	0.00%	-6.84%	-8.98%	0.59%	-
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,123.91	37.80	$1.00T	0.60%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	269.12	31.22	$648.55B	1.98%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	248.78	70.48	$439.62B	2.78%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	148.46	118.77	$366.28B	2.31%	-	6.96%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	400.84	25.74	$359.79B	2.47%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	137.70	20.80	$261.73B	3.36%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	160.04	23.99	$248.20B	2.00%	15.97%	21.96%	9.82%	45.96%
9	TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA	603.02	32.49	$222.97B	0.29%	8.14%	13.51%	8.81%	12.95%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Dec 2013	Mar 2014	Jun 2014	Sep 2014	Dec 2014	Mar 2015	Jun 2015	Sep 2015	Mar 2016	Jun 2016	Sep 2016	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	796.00K	959.00K	823.00K	917.00K	1.20M	1.05M	1.48M	1.65M	2.05M	2.11M	2.24M	2.14M	2.53M	2.45M	2.29M	2.83M	3.65M	4.57M	3.48M	4.51M	5.28M	4.93M	5.65M	6.77M	6.70M	6.71M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.79M	3.23M	3.76M	3.57M	3.99M
Gross Profit	2.08M	2.49M	2.39M	1.72M	2.62M	285.00K	-23.00K	-115.00K	-269.00K	263.00K	134.00K	66.00K	-24.00K	-77.00K	24.00K	175.00K	-11.00K	38.00K	172.00K	28.00K	125.00K	171.00K	377.00K	468.00K	751.00K	528.00K	703.00K	773.00K	436.00K	749.00K	1.37M	1.89M	920.00K	1.72M	2.28M	2.14M	2.43M	3.00M	3.13M	2.73M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.00M	3.25M	3.07M	2.59M	4.15M
Operating Income	-	-3.54M	-3.96M	-3.99M	-	-1.97M	-2.40M	-2.26M	-2.24M	-285.00K	-363.00K	-596.00K	-801.00K	-3.63M	-2.45M	-2.18M	-4.12M	-2.06M	-2.29M	-2.36M	-2.20M	-2.26M	-2.43M	-2.14M	-2.13M	-2.44M	-4.81M	-2.43M	-3.23M	-3.03M	-2.29M	-1.45M	-2.07M	-1.21M	-597.00K	-859.00K	-824.00K	-61.00K	542.00K	-1.43M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-442.00K	519.00K	367.00K	1.02M	-971.00K
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	25.00K	23.00K	9.00K	16.00K	15.00K
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-884.00K	74.00K	-79.00K	526.00K	-1.44M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Net Income	-3.98M	-4.18M	-3.89M	-80.00K	-5.79M	-3.04M	-3.27M	-7.30M	-3.26M	-444.00K	-499.00K	-758.00K	-3.68M	-6.28M	-2.44M	-2.83M	-3.85M	-1.65M	-5.91M	-1.90M	-3.21M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-884.00K	74.00K	-79.00K	526.00K	-1.44M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.08	-0.14	-0.08	-0.20	-0.09	-2.79	-2.61	-1.88	-1.04	-1.46	-0.83	-0.42	-0.59	0.05	-0.05	-	-0.81
R&D Expense	-	745.00K	785.00K	641.00K	-	451.00K	468.00K	455.00K	270.00K	402.00K	393.00K	134.00K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	22.02M	20.05M	31.97M	31.48M	27.54M	1.24M	1.93M	1.72M	2.03M	3.45M	4.09M	7.43M	-	9.41M	15.20M	18.53M	24.05M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	6.90M	9.18M	10.97M	13.34M
Gross Profit	11.61M	9.76M	18.44M	13.13M	10.75M	-935.00K	-11.00K	753.00K	292.00K	225.00K	219.00K	1.15M	-	2.51M	6.02M	7.56M	10.71M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	15.31M	13.64M	11.78M	11.91M
Operating Income	-1.90M	-3.61M	-2.97M	-9.50M	-15.76M	-10.57M	-8.92M	-1.71M	-15.51M	-13.91M	-10.99M	-9.15M	-	-12.80M	-7.62M	-4.22M	-1.20M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-10.65M	-4.32M	-2.70M	1.46M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	12.00K	18.00K	74.00K	73.00K
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-12.18M	-5.85M	-4.29M	-363.00K
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0
Net Income	-1.92M	-3.13M	-9.78M	-8.33M	-15.99M	-13.94M	-32.95M	-2.23M	-20.69M	-15.69M	-13.24M	-13.97M	-	-12.20M	-5.85M	-4.29M	-363.00K
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-0.85	-	-10.73	-4.51	-2.93	-0.23
R&D Expense	3.18M	2.31M	2.22M	2.49M	3.21M	2.25M	1.85M	0	500.00K	1.10M	1.20M	1.20M	1.30M	1.70M	1.70M	1.30M	1.60M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	32.03M	33.56M	38.79M	30.28M	30.01M	4.82M	842.00K	27.26M	21.61M	19.51M	20.71M	-	21.50M	18.10M	17.00M	21.32M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5.71M	3.68M	3.45M	6.04M
Cash & Equivalents	4.77M	5.64M	3.45M	4.95M	4.50M	1.63M	1.61M	235.00K	51.00K	421.00K	381.00K	848.00K	2.66M	-	3.44M	1.50M	1.39M	2.65M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	708.00K	384.00K	724.00K	935.00K
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.04M	1.30M	799.00K	1.98M
Total Liabilities	-	-	22.07M	22.51M	18.52M	18.83M	23.45M	17.64M	7.30M	14.23M	15.48M	6.31M	6.55M	-	5.14M	3.67M	4.90M	6.76M
Current Liabilities	-	-	8.25M	16.33M	15.27M	8.62M	11.99M	16.98M	3.01M	10.04M	13.77M	4.33M	4.66M	-	4.36M	3.14M	4.27M	3.75M
Long Term Debt	-	-	8.64M	4.94M	0	6.32M	7.38M	0	4.13M	2.83M	253.00K	198.00K	362.00K	-	134.00K	106.00K	77.00K	47.00K
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.39M	1.12M	1.25M	3.65M
Total Equity	13.21M	11.66M	8.50M	11.05M	20.27M	11.45M	6.55M	-2.10M	-6.46M	13.03M	6.12M	13.21M	14.13M	-	16.30M	14.43M	12.09M	14.56M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.14M	1.42M	1.49M	1.78M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	1.27M	-1.72M	220.00K	-10.20M	-8.47M	-13.70M	-12.38M	-959.00K	-6.69M	-6.75M	-9.14M	-7.43M	-	-7.72M	-3.56M	439.00K	685.00K
Investing Cash Flow	-377.00K	-6.23M	-508.00K	-4.88M	-1.77M	3.62M	1.79M	1.01M	-42.00K	-97.00K	-55.00K	-96.00K	-	-277.00K	-126.00K	-223.00K	-326.00K
Financing Cash Flow	0	5.76M	1.73M	14.60M	7.37M	10.07M	8.99M	775.00K	7.10M	6.81M	9.66M	9.34M	-	-225.00K	1.74M	-329.00K	903.00K
Capital Expenditure	-351.00K	-192.00K	-231.00K	-882.00K	-605.00K	-130.00K	-204.00K	-19.00K	-143.00K	-97.00K	-55.00K	-151.00K	-	-277.00K	-126.00K	-223.00K	-326.00K
Free Cash Flow	916.00K	-1.91M	-11.00K	-11.09M	-9.08M	-13.83M	-12.58M	-978.00K	-6.83M	-6.85M	-9.20M	-7.58M	-	-8.00M	-3.69M	216.00K	359.00K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-	-8.22M	-1.94M	-113.00K	1.26M

Ratios (Annual)

Figures in %.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	52.7%	48.7%	57.7%	41.7%	39.0%	-75.4%	-0.6%	43.7%	14.4%	6.5%	5.3%	15.5%	-	26.7%	39.6%	40.8%	44.5%
Operating Margin %	-8.6%	-18.0%	-9.3%	-30.2%	-57.2%	-852.3%	-462.4%	-99.4%	-763.0%	-403.5%	-268.5%	-123.1%	-	-136.0%	-50.1%	-22.7%	-5.0%
Net Margin %	-8.7%	-15.6%	-30.6%	-26.5%	-58.0%	-1,124.4%	-1,708.3%	-129.3%	-1,017.9%	-455.2%	-323.4%	-188.0%	-	-129.7%	-38.5%	-23.1%	-1.5%
ROE %	-16.5%	-36.9%	-88.5%	-41.1%	-139.7%	-212.8%	1,571.5%	34.5%	-158.9%	-256.3%	-100.3%	-98.8%	-	-74.9%	-40.6%	-35.5%	-2.5%
ROCE %	-	-15.2%	-17.2%	-40.4%	-72.8%	-58.7%	73.3%	78.9%	-90.1%	-177.4%	-72.4%	-57.0%	-	-74.6%	-50.9%	-33.1%	-6.8%

Shareholding Pattern

Insiders

12.63%

Institutions

17.71%

Public Float

20.27%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Vanguard Capital Management LLC	2.58%	46.15K	$1.22M
2	Blackrock Inc.	1.94%	34.66K	$916.97K
3	Geode Capital Management, LLC	1.04%	18.69K	$494.56K
4	Renaissance Technologies, LLC	0.90%	16.20K	$428.62K
5	Citadel Advisors Llc	0.82%	14.71K	$389.33K
6	Vanguard Fiduciary Trust Co	0.53%	9.41K	$248.91K
7	Xtx Topco Ltd	0.53%	9.45K	$250.05K
8	Dimensional Fund Advisors LP	0.47%	8.40K	$222.16K
9	UBS Group AG	0.02%	343	$9.07K
10	Wells Fargo & Company	-	50	$1.32K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PRPO

Google News Fri, 04 Sep 2026

Precipio Inc (NASDAQ: PRPO) Share Price, PRPO Stock News, PRPO Share Price & Updates - kalkine.ca

<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE1ZVHJBdF9PT0N3YjByNkZ5MGhPamJFVVQ0MGY0QXJ6QW1sUDYwTFJiUzBCZWZyTEN6dE9qQW5TcnB4Yk1rSXpPU29PeU01aU44?oc=5" target="_blank">Precipio Inc (NASDAQ: PRPO) Share Price, PRPO Stock News, P…

Google News Sat, 05 Sep 2026

(PRPO) Volatility Zones as Tactical Triggers - Stock Traders Daily

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQNVBBakpoci1zdkZrMkc5dURTbEYzSHF0aWZoSzlEMVBZYUt2azJRNGhsNjE1THBaSnpTenRLbmtkemNzR1pON1dyS0ZtNC15ODFuS0xFQUozZmQtYVd3UHE2TDRlYTBWSVNtZGxkWnJGa2VLZG5DcEdsRFBESDloeGZ4VENGcllmZFh5Rl…

Google News Fri, 04 Sep 2026

Precipio Inc (NASDAQ: PRPO) Share Price, PRPO Stock News, PRPO Share Price & Updates - kalkine.com.au

<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE1ING1HRGU2TDA5SFo2OVpZb3hPdi1wbUFrVTNGb0tGT3FLb1E2SkNISi1TNk5HYk1YdDZSekVBSkxjbUZJTXk2SWN0cW9vVlVpOURuZFNn?oc=5" target="_blank">Precipio Inc (NASDAQ: PRPO) Share Price, PRPO Stock…

Google News Mon, 24 Aug 2026

PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now? - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxNSjlFeXo1Z1hYZEI4Tl9ZeU84NUhXTDlzMkJUZFdVZzlVYUFRZUFVbnpONFVvVDk1RHg3WU1BaENBRWpHQUg3LVZ0eVlnSE9KcXhyQ2N6UlY3Mmg0SGRUQndsOVB0cXBCTHlRUFB6M0ZRMVhnVnJQS180SGdPYWZkbHk0WU1JZ3luZzM1d0…

Google News Sun, 23 Aug 2026

PRPO | Precipio, Inc. Common Stock Financials - Revenue Breakdown - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTFBGb1hVSldYZzhmaUVyNTdWQXFTOWh6bVRyS0VIQ0oxVW1XaG9WTy1WWFk0dUhJUnk1OHpRcjRKbjhYaC14TzVYS3BVZW4zUGtTc0dqRFFtTXlvcWpYWTlyQTU2RjJLekoxTi04dVdhNHZUVEJSVXhJ?oc=5" target="_blank">PRPO | …

Google News Fri, 31 Jul 2026

Precipio to Take Live Investor Questions During Aug. 17 Call - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQTFZoeDBTWTdKUkxQeTJPRXE2bVdHR2o1Y09VRTBCVlB5eFhMckxyRWZIZ3VyUTB5dWpiYzZGZmFFbHRSR3dKMHA2eUdXZFc5eTlzV1c0TVNMV1AtSzVjSTR6SHU2czFZQVJ0dEhUWjNGZ0ltRV9VVkFjY1RGSWpjWWxmTlljaEpfMlRuQV…

PRPO — Frequently Asked Questions

What is the current share price of Precipio, Inc. (PRPO)?

As of 2026-09-19 21:16 PDT, Precipio, Inc. (PRPO) trades at $27.25 on NasdaqCM. Its 52-week range is $14.19 to $32.37.

What is the market capitalisation of PRPO?

Precipio, Inc. (PRPO) has a market capitalisation of $48.78M on NasdaqCM.

What is the P/E ratio of PRPO?

PRPO trades at a trailing price-to-earnings (P/E) ratio of -43.95. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 3.21.

What is the return on equity (ROE) of PRPO?

PRPO has a return on equity (ROE) of -8.98%. Its return on capital employed (ROCE) is -6.84%.

Is PRPO a good stock to buy?

This page provides a data-driven analysis of Precipio, Inc. (PRPO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Precipio, Inc. PRPO PHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Precipio Inc (NASDAQ: PRPO) Share Price, PRPO Stock News, PRPO Share Price & Updates - kalkine.ca

(PRPO) Volatility Zones as Tactical Triggers - Stock Traders Daily

Precipio Inc (NASDAQ: PRPO) Share Price, PRPO Stock News, PRPO Share Price & Updates - kalkine.com.au

PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now? - finance.yahoo.com

PRPO | Precipio, Inc. Common Stock Financials - Revenue Breakdown - Quiver Quantitative

Precipio to Take Live Investor Questions During Aug. 17 Call - Stock Titan

PRPO — Frequently Asked Questions

What is the current share price of Precipio, Inc. (PRPO)?

What is the market capitalisation of PRPO?

What is the P/E ratio of PRPO?

What is the return on equity (ROE) of PRPO?

Is PRPO a good stock to buy?

Explore More